z-logo
open-access-imgOpen Access
YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR L858R, T790M ‐mutant resistance in vitro and in vivo
Author(s) -
Zhang Zhang,
Zou Jian,
Yu Lei,
Luo Jinfeng,
Li Yan,
Tu Zhengchao,
Ren Xiaomei,
Wei Hongcheng,
Song Liyan,
Lu Xiaoyun,
Ding Ke
Publication year - 2018
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.1392
Subject(s) - t790m , pharmacokinetics , gefitinib , in vivo , pharmacology , bioavailability , ic50 , mutant , in vitro , apoptosis , oral administration , medicine , chemistry , epidermal growth factor receptor , cancer research , cancer , biology , biochemistry , microbiology and biotechnology , gene
YL143 was identified as a novel wild‐type sparing EGFR T790M inhibitor with good pharmacokinetic properties. It potently suppresses EGFR L858R/T790M with an 50% inhibitory concentration (IC 50 ) value of 2.0 ± 0.3 nmol/L, but is approximately 92‐folds less potent against EGFR WT kinase. YL143 suppresses cellular proliferation and induces G0/G1 phase arrest and apoptosis in H1975 cells with EGFR L858R/T790M mutation at 30 nmol/L. It also exhibits acceptable pharmacokinetics (PK) parameters with an oral bioavailability value of 25.0% after oral administration in rats and exhibits promising antitumor efficacy in a gefitinib‐resistant human H1975 xenografted model after oral administration of 30 mg/kg/day. These data supported that YL143 could be a promising lead compound for overcoming clinical EGFR T790M resistance of patients with non‐small‐cell lung cancer (NSCLC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here